Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Justin Hovey, FAAP, FACP, DABOM

Obesity Medicine · Noland Hospital Dothan II

View

Dr. Kimberly Gudzune

Obesity Medicine · JHU

View

Dr. Reema Dbouk

Obesity Medicine · Emory University

View

Dr. Jennifer Paisley

Obesity Medicine · St. Elizabeth Medical Center

View

Dr. Jesse Richards

Obesity Medicine · OUHSC

View

Dr. Alexandra Sowa

Obesity Medicine · SoWell

View

Dr. Eduardo Grunvald

Obesity Medicine · UCSD

View

Dr. Melanie Jay

Obesity Medicine · NYU

View

Dr. Stephanie Fein

Obesity Medicine

View

Dr. Rebecca Andrews

Primary Care · UCHC

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    AFDr. Angela Fitch

    Dr. Angela Fitch

    Internal Medicine · Obesity Medicine & Nutrition
    Knownwell
    angelafitch
    Boston, MA, USA

    Research

    Fixed-dose, extended-release combination of naltrexone and bupropion reduces craving and body weight: A pooled post hoc analysis

    2026

    Via Obes Res Clin Pract

    Research

    Real-world healthcare resource utilization and medical costs in patients with overweight or obesity and multimorbidity treated with semaglutide in the United States

    2026

    Via Expert Review of Pharmacoeconomics & Outcomes Research

    Research

    Use of Naltrexone-Bupropion in Persons With Overweight/Obesity and Symptoms of Depression: A Pooled Analysis

    2026

    Via Obesity (Silver Spring)

    Research

    Identifying Predictors of Weight-Related Outcomes With Fixed-Dose, Extended-Release Naltrexone and Bupropion Among Treatment-Adherent Patients in Phase 3 COR Trials: A Treatment Target Analysis

    2026

    Via Obesity Science & Practice

    Research

    Changes in food cravings, dietary quality, body composition, and dietary intake during GLP-1 receptor agonist therapy: The CRAVE study

    2026

    Via Obesity Pillars

    Research

    Employee perceptions and experiences with tirzepatide treatment for obesity or overweight in the US: Insights from the PERCEPTIONS Survey

    2026

    Via Obesity Pillars

    Research

    Tirzepatide Was Associated with Improved Health-Related Quality of Life in Adults with Obesity or Overweight and Type 2 Diabetes: Results from the Phase 3 SURMOUNT-2 Trial

    2025

    Via Diabetes Therapy

    Research

    Setting Expectations When Prescribing Medication for the Treatment of Patients With Obesity

    2025

    Via Mayo Clinic Proceedings: Innovations, Quality & Outcomes

    Research

    Impact of semaglutide 2.4 mg on healthcare resource utilization and medical costs in patients with atherosclerotic cardiovascular disease in the United States (SHINE-ASCVD)

    2025

    Via Journal of Medical Economics

    Research

    Patient Perspectives on Weight Management and Wellness After Liver Transplantation: A Convergent Mixed Methods Study

    2025

    Via Journal of Surgical Research

    Research

    Impact of Semaglutide 2.4 mg on Healthcare Resource Utilization and Medical Costs in Patients With Heart Failure in the United States (SHINE-HF)

    2025

    Via Clinical Therapeutics

    Research

    Effects of semaglutide on one-year medical costs among patients with obesity or overweight in US real world setting

    2025

    Via Expert Review of Pharmacoeconomics & Outcomes Research

    Research

    Application of nutrition interventions with GLP-1 based therapies: A narrative review of the challenges and solutions

    2025

    Via Obesity Pillars

    Research

    Optimizing GLP-1 therapies for obesity and diabetes management

    2025

    Via Obesity Pillars

    Research

    Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1 based therapies: An expert consensus statement using a modified Delphi approach

    2025

    Via Obesity Pillars